ArticleJournal of patient-reported outcomes2026
Content validation of the Myelofibrosis Symptom Assessment Form version 4.0 (MFSAF v4.0) in Janus kinase inhibitor-experienced patients with myelofibrosis.
Article in Journal of patient-reported outcomes, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- A phase I/IIa trial of PXS-5505, a novel pan-lysyl oxidase inhibitor, in advanced myelofibrosis.Haematologica · 2025Trial
- Assessment of the MFSAF v4.0 and PROMIS Fatigue 7a to Measure Outcomes in Myelofibrosis: Validation from a Non-interventional Mixed Methods Study.Advances in therapy · 2026Observational
- From symptom scales to regulatory endpoints: the evolution and clinical impact of patient-reported outcome measures in myeloproliferative neoplasms.Clinical and experimental medicine · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Patients with myelofibrosis (MF) experience debilitating symptoms that negatively impact health-related quality of life and functioning. The Myelofibrosis Symptom Assessment Form version 4.0 (MFSAF v4.0) is a 7-item questionnaire assessing the burden of MF symptoms, including fatigue, night sweats, pruritus, abdominal discomfort, pain under the left ribs, early satiety, and bone pain. This study evaluated the content validity of the MFSAF v4.0 in Janus kinase (JAK) inhibitor-experienced participants with MF. Qualitative interviews were conducted with 20 symptomatic (MFSAF Total Symptom Score ≥ 10) participants from the US (n = 5) and UK, Germany, Italy, Poland, and Spain (n = 3 each). The interviews began with concept elicitation to allow patients to spontaneously report important symptoms. Next, content validation determined if the MFSAF v4.0 items and numeric rating scale (NRS) were relevant, important, and understandable. Overall, participants showed a clear understanding of the MFSAF v4.0, and no more than 3 (15%) mentioned that a given item was not relevant to their experience. Participants consistently felt that it was easy to select an answer on the NRS and often indicated that an improvement of 2 to 4 points was meaningful. These findings support the MFSAF v4.0 as a content-valid measure of selected disease-related symptoms for patients with JAK inhibitor-experienced MF.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.